Altimmune (ALT.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Event Tracking

Nov11

Altimmune Inc. Releases Pemvidutide Phase 2b Clinical Trial Results for MASH Treatment

14:37

Nov6

Altimmune released FY2025 Q3 earnings on November 6 During-Market (EST), actual revenue USD 5K (forecast USD 560), actual EPS USD -0.2126 (forecast USD -0.2628)

21:00

Altimmune released FY2025 9 Months Earnings on November 6 During-Market EST, actual revenue USD 15 K, actual EPS USD -0.7435

21:00

Oct30

Altimmune to release FY2025 Q3 earnings report on November 6, during market hours EST, with forecast revenue of USD 560 and EPS of USD -0.2628

00:11

Oct29

Trucchio Analyzes Healthcare Industry Stocks

10:42

Oct27

Altimmune Conducts Second Phase Clinical Trial for Pemvidutide in Treating AUD

18:32

Schedules & Filings

Schedules

Filings

Nov6

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 5 K, Net Income -19.01 M, EPS -0.2126

Aug12

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 5 K, Net Income -22.15 M, EPS -0.2718

May13

Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 5 K, Net Income -19.58 M, EPS -0.2591

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change